Skip to main content
. 2018 Sep 11;19(9):2697. doi: 10.3390/ijms19092697

Figure 4.

Figure 4

Vincristine in co-treatment with FK506 decreases tumor growth in vivo. A subcutaneous tumor was generated in Sprague-Dawley rats with C6-derived GSCs. Ten days post-inoculation, rats were treated with vehicle (black), FK506 (blue; 2.25 mg/kg/72 h/intravenous), Vc (green; 0.3 mg/kg/72 h/intravenous) or FK506/Vc (red) for seven days. The graph represents tumor volume (in cm3) over a total of 17 days. Graphs represent the mean ± S.D. ** p < 0.01 and *** p < 0.001 versus vehicle. n = 4.